Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Russell A. Miller, Qingwei Chu, Jianxin Xie, Marc Foretz, Benoit Viollet and Morris J. Birnbaum ()
Additional contact information
Russell A. Miller: Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania
Qingwei Chu: Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania
Jianxin Xie: Cell Signaling Technology, Inc., 3 Trask Lane, Danvers, Massachusetts 01923, USA
Marc Foretz: Inserm, U1016, Institut Cochin
Benoit Viollet: Inserm, U1016, Institut Cochin
Morris J. Birnbaum: Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania

Nature, 2013, vol. 494, issue 7436, 256-260

Abstract: Biguanides such as metformin, which is the most widely prescribed drug for type-2 diabetes, are shown to antagonize the actions of glucagon by decreasing the levels of cyclic AMP.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature11808 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:494:y:2013:i:7436:d:10.1038_nature11808

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature11808

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().